 Grifols MCE:GRF, MCE:GRF.P NASDAQ:GRFS, a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin IG innovation, XEMBIFY immune globulin subcutaneous human-klhw, the companys first 20 subcutaneous immunoglobulin therapy for the treatment of patients 2 years of age and older with primary immunodeficiency PI. 